On December 22, 1987, the first conjugate vaccine was licensed by the Food and Drug Administration for the prevention of infections due to Haemophilus influenzae type b. This vaccine is a conjugate of H influenzae type b capsular polysaccharide and diphtheria toxoid, and is officially designated as Haemophilus b Conjugate Vaccine (Diphtheria Toxoid-Conjugate). The purpose of this statement is to provide background information, perspective and recommendations for the use of this product.

This content is only available via PDF.